Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021
European Cancer Organisation - Time to Act
Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands
European Cancer Organisation - Time to Act ( Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands )
19 May 2021
European Cancer Organisation: Time To Act
Professor Mark Lawler - Queens University Belfast, Belfast, UK
European Cancer Organisation: Time To Act ( Professor Mark Lawler - Queens University Belfast, Belfast, UK )
19 May 2021
Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems
Special issue authors and funders
Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems ( Special issue authors and funders )
16 May 2021
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small ce...
Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )
4 May 2021
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA
Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )
26 Apr 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Apr 2021
Understanding patient experience in Europe: The first Global Lung Cancer Coaliti...
Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England
Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey ( Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England )
22 Apr 2021
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients w...
Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )
19 Apr 2021
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world ( Dr Martina Lorenzi - University of Padua, Padua, Italy )
16 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 c...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021